Scope of report
- The report provides a snapshot of the global therapeutic landscape of Lysosomal storage disease.
- The report assesses Lysosomal storage disease pipeline based on highest phase of development, type of sponsor, mechanism of action (MoA), route of administration (RoA), and molecule type.
- The report reviews Lysosomal storage disease pipeline by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The report covers pipeline products based on various stages of development for Lysosomal storage disease ranging from discovery to pre-registration and undisclosed stages.
Protiva Biotherapeutics, Neuraltus Pharmaceuticals, Aldagen, Orphazyme, Oxyrane, AngioChem, GlaxoSmithKline, Shire, Nimbus Discovery, Genzyme Corporation, Bionaturis, REGiMMUNE, Turing Pharmaceuticals, Sharp Edge Labs, DORPHAN S.A., Dover Lifesciences, Promosome, RaNeDis Pharmaceuticals, Amicus Therapeutics, biOasis Technologies, Neuralstem
NP 003, ALD 601, Filgrastim biosimilar, TRP 001, RND 001, Alpha galactosylceramide liposomal, NSI 566
Format: Microsoft Excel
- Single Use: $300
- Site License: $500
- Global License: $800